Home › Funds › EXCHANGE TRADED CONCEPTS TRUST › ROBO Global(R) Healthcare Technology and Innovation ETF
Fund family: EXCHANGE TRADED CONCEPTS TRUST · Filed by EXCHANGE TRADED CONCEPTS TRUST (CIK 1452937) · SEC series S000065730
Ticker: HTEC (C000212575)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 682 with, 7 against, 0 abstentions (not counted as with management). Shareholder proposals: 7 FOR, 0 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as EXCHANGE TRADED CONCEPTS TRUST’s manager page (11,122 ballot items across 22 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | EXCHANGE TRADED CONCEPTS TRUST | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 90.7% | 605 | 90.9% | 9,258 |
| Backed environmental and social shareholder proposals at US companies | n/a | 0 | 16.4% | 317 |
Each ballot item this fund voted is set against the votes of the other EXCHANGE TRADED CONCEPTS TRUST funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most EXCHANGE TRADED CONCEPTS TRUST funds on 5 items (9.3% of the 54 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most EXCHANGE TRADED CONCEPTS TRUST funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Company | 2026-05-05 | Shareholder Shareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director | For | AGAINST — 3 of 3 EXCHANGE TRADED CONCEPTS TRUST funds | Against | Not approved, 27.6% support |
| Regeneron Pharmaceuticals, Inc. | 2026-06-12 | Election of Directors: Christine A. Poon | Against | FOR — 3 of 3 EXCHANGE TRADED CONCEPTS TRUST funds | Against | Elected, 76.8% support |
| Regeneron Pharmaceuticals, Inc. | 2026-06-12 | Election of Directors: Craig B. Thompson, M.D. | Against | FOR — 3 of 3 EXCHANGE TRADED CONCEPTS TRUST funds | Against | Elected, 79.3% support |
| Incyte Corporation | 2026-06-08 | Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Julian C. Baker | For | AGAINST — 3 of 4 EXCHANGE TRADED CONCEPTS TRUST funds | For | Elected, 80.9% support |
| Globus Medical, Inc. | 2026-06-03 | Election of two Class II directors to serve until the 2029 Annual Meeting of Stockholders: Keith W. Pfeil | Withhold | FOR — 3 of 4 EXCHANGE TRADED CONCEPTS TRUST funds | Against | Elected, 91.3% support |
Download all 5 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 71.7% of this fund’s 689 such votes could be given a sector; the other 195 (28.3%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 402 | 5 | 1.2% |
| Industrials | 54 | 2 | 3.7% |
| Technology | 27 | 0 | 0.0% |
| Miscellaneous | 11 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 409 | 0 |
| Corporate Governance | 81 | 5 |
| Audit-related | 60 | 0 |
| Say-on-Pay | 53 | 0 |
| Compensation | 49 | 1 |
| Capital Structure | 38 | 0 |
| Extraordinary Transactions | 3 | 0 |
| Shareholder Rights and Defenses | 2 | 1 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Moderna, Inc. | November 12, 2025 | $6M | 2 | 0 |
| Moderna, Inc. | May 6, 2026 | $6M | 5 | 0 |
| CareDx, Inc. | June 11, 2026 | $3M | 9 | 0 |
| Twist Bioscience Corporation | February 5, 2026 | $3M | 5 | 0 |
| Axogen, Inc. | June 23, 2026 | $2M | 10 | 0 |
| Glaukos Corporation | May 28, 2026 | $2M | 4 | 0 |
| GRAIL, Inc. | June 18, 2026 | $2M | 3 | 0 |
| Adaptive Biotechnologies Corporation | June 5, 2026 | $2M | 4 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 13, 2026 | Vertex Pharmaceuticals Incorporated | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | For | Against |
| April 23, 2026 | IQVIA Holdings Inc. | If properly presented, a stockholder proposal concerning separate Chairman and Chief Executive Officer roles. Shareholder proposal | For | Against |
| May 15, 2026 | Medpace Holdings, Inc. | Stockholder proposal regarding giving shareholders an ability to call for a special shareholder meeting, if properly presented at the meeting. Shareholder proposal | For | Against |
| May 5, 2026 | Bristol-Myers Squibb Company | Shareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director Shareholder proposal | For | Against |
| April 21, 2026 | Bio-Rad Laboratories, Inc. | Stockholder proposal regarding dual class capital structure. Shareholder proposal | For | Against |
| April 28, 2026 | Revvity, Inc. | To approve the shareholder proposal regarding Executives to Retain Significant Stock. Shareholder proposal | For | Against |
| April 30, 2026 | Boston Scientific Corporation | Stockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting." Shareholder proposal | For | Against |
695 ballot items at 64 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, ROBO Global(R) Healthcare Technology and Innovation ETF (HTEC) voted at 64 shareholder meetings of 60 companies, on 695 ballot items in all. Where management made a recommendation, the fund followed it on 99.0% of the items and voted against it 7 times. Its most frequent area of disagreement was corporate governance (5 of its votes against management). It voted on 7 shareholder proposals. It voted FOR the board's own proposals about as often as EXCHANGE TRADED CONCEPTS TRUST's funds as a whole (90.7% against 90.9%). It voted differently from most EXCHANGE TRADED CONCEPTS TRUST funds on 5 items.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of EXCHANGE TRADED CONCEPTS TRUST’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.